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Accommodation refers to a condition in which a transplant
sustains little or no injury and functions normally despite
the presence of anti-donor antibodies in the circulation of
the recipient. We first observed accommodation in the
1980’s in the setting of ABO-incompatible kidney trans-
plantation. At that time, 75% of kidneys incompatible for
blood group-A or -B were rejected within 3 months. How-
ever, Guy Alexandre and a few others found that rejection
could be averted and enduring function achieved if the of-
fending antibodies were depleted at the time of surgery.
Probing the surprising success we found that in some re-
cipients the anti-blood antibodies returned to the circu-
lation and in all cases the kidneys continued to express
the corresponding antigen. We figured then that the grafts
might have acquired resistance to injury (1). After observ-
ing a similar phenomenon in cardiac xenografts, we ap-
plied the term ‘accommodation’ to denote the possibility
that the graft and/or recipient had changed in such a way
that what was once lethal was no longer so (2). Notwith-
standing occasional reports on highly sensitized recipients
(3), accommodation has been seen rarely in recipients pre-
sensitized to HLA (perhaps because anti-HLA antibodies
include high affinity IgG, presumably reflecting somatic hy-
permutation characteristic of T cell-dependent and not T
cell-independent responses that attack blood group and
xenogeneic antigens) and de novo produced anti-HLA an-
tibodies presage bad outcomes (4). Whether accommo-
dation can be achieved reliably in presensitzed recipients,
how it occurs and why it is not seen more often should
compel interest.
In this issue of AJT, Chen et al. (5) report that monkeys pre-
viously sensitized by skin transplantation and treated with
cobra venom factor (CVF) and with conventional immuno-
suppression agents can accept kidney grafts. The monkeys
had anti-donor antibodies both before and after transplan-
tation and the grafts had normal histology indicating the
establishment (or development if you wish) of accommo-
dation. Clearly then, accommodation can be achieved in
presensitized primates and that answer should excite clin-
icians and scientists.
Although Chen and co-workers did not attempt to test how
accommodation occurs, their discussion nicely frames this
question by commenting that CVF might “bring about” ac-
commodation or “allow it to assert itself” by preventing
destruction of the graft. The latter explanation seems most
appealing to the authors as they call the CVF used “an ex-
tremely potent anti-complement protein”. This CVF might
allow anti-MHC antibodies to induce protective changes,
as described independently from the laboratories of Dal-
masso (6), Delikouras (7) and Jindra (8), rather than injury.
On the other hand, the CVF used might actually induce
accommodation, not by inhibiting complement but rather
by activating it. The CVF from Naja kaouthia (Naja kaouthia
CVF) activates both C3 and C5, generating C3a and C5a and
it generates small amounts of terminal complexes that can
insert in cell membranes, causing ‘reactive lysis’ of sus-
ceptible cells, like heterologous erythrocytes, and possibly
protection of less susceptible cells, such as endothelial
cells. The answer to whether it is anti-MHC antibodies
and/or activated complement proteins (or something else)
that protects grafts from lethal injury could eventuate in
new therapeutics in many fields.
If anti-MHC antibodies, which some think are made by
most graft recipients, can induce both rejection and ac-
commodation, why is accommodation not seen more of-
ten? Chen et al. (5) seem to think the amount of anti-MHC
antibody produced explains the outcome—large amounts
cause rejection, small amounts accommodation. Consis-
tent with this view they note that monkeys treated with
CVF had lower levels of anti-donor antibodies than mon-
keys not given CVF and take from this result that “ . . .
CVF significantly attenuated [the] induced antibody re-
sponse . . . ”. However, we and others before us have ob-
served that perfused organs and organ grafts can absorb
huge amounts of anti-donor antibodies from blood and in
some cases anti-donor antibodies may not be seen at all
until a graft is rejected or removed (9). Thus, if accommoda-
tion allows a graft to continue being perfused it will enable
removal of much or all of the anti-MHC antibody produced,
while rejection, whether triggered or not by antibodies,
will prevent absorption by decreasing the rate blood flows
through the graft. One implication of the second potential
mechanism is that assays for anti-donor antibodies may
well underestimate or entirely miss humoral responses to
a graft donor and hence accommodation. If that is so then
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we will not see accommodation in many cases when it is
present and our original definition of accommodation, the
simultaneous presence of anti-donor antibodies and an un-
blemished graft, should be abandoned. Nor do the results
of Chen et al. encourage detection of “protective genes
or proteins” as a marker of accommodation because they
show (but do not discuss), that these genes and proteins
are also seen in rejection. To understand better what ac-
commodation is and how prevalent it may be, we need a
better way of seeing it.
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